ここから本文です
875

もーりぃー 強く買いたい 2017年12月17日 17:30

みなさん こんばんわ
海外サイト見てましたら・・こんなん記事が・・
翻訳システムで検索してみてください。 では・・

More notable recent Astellas Pharma Inc. (OTCMKTS:ALPMF) news were published by: Prnewswire.com which released: “Astellas Pharma Chooses Verizon Secure Cloud Interconnect to Centralize Global …” on December 06, 2017, also Prnewswire.com with their article: “Astellas Acquires Mitobridge Under Existing Collaboration” published on December 01, 2017, Prnewswire.com published: “Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in …” on December 11, 2017. More interesting news about Astellas Pharma Inc. (OTCMKTS:ALPMF) were released by: Prnewswire.com and their article: “Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma …” published on December 04, 2017 as well as Prnewswire.com‘s news article titled: “Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute …” with publication date: November 28, 2017.

Astellas Pharma Inc., a pharmaceutical company, makes, markets, and imports and exports pharmaceutical products worldwide. The company has market cap of $25.55 billion. The firm offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It has a 16.04 P/E ratio. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.